Avera Medical Group Transplant & Liver Surgery, Avera McKennan Hospital & University Health Center, Sioux Falls, South Dakota; Department of Surgery, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota.
Avera Medical Group Transplant & Liver Surgery, Avera McKennan Hospital & University Health Center, Sioux Falls, South Dakota; Department of Surgery, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota; Department of Internal Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota.
Transplant Proc. 2020 Nov;52(9):2790-2794. doi: 10.1016/j.transproceed.2020.06.006. Epub 2020 Jul 5.
Cryptococcal infection (CI) is an uncommon fungal disease that poses a particular fatal risk to liver transplant (LT) recipients because of the potential rapid development and dissemination of the disease. Depending on the pathophysiology, CI may manifest with a wide range of clinical presentations that may delay early diagnosis and timely treatment. Additionally, most anticryptococcal therapies may threaten LT recipients owing to the associated hepatotoxicity of these medications. We report a case of a 25-year-old woman who received an LT for cryptogenic cirrhosis and developed rapidly progressive CI with pulmonary, myocardial, and cerebral involvement within a month of transplantation. She presented with severe pulmonary hypertension refractory to medical management and subsequently died despite our efforts. Herein, we review the etiology of cryptococcosis, the natural history of cryptococcal disease, and standard treatments for CI, and we highlight peculiarities of Cryptococcus neoformans infection in solid organ transplant recipients.
隐球菌感染(CI)是一种罕见的真菌感染病,由于疾病的快速发展和传播,对肝移植(LT)受者构成特别致命的风险。根据病理生理学,CI 可能表现出广泛的临床表现,可能会延迟早期诊断和及时治疗。此外,由于这些药物的肝毒性,大多数抗隐球菌治疗可能会威胁 LT 受者。我们报告了一例 25 岁女性,因隐源性肝硬化接受 LT,在移植后一个月内出现肺部、心肌和脑部受累的快速进展性 CI。她表现为严重的肺动脉高压,对药物治疗无反应,尽管我们努力治疗,但仍死亡。在此,我们回顾了隐球菌病的病因、隐球菌病的自然病程以及 CI 的标准治疗方法,并强调了新型隐球菌感染在实体器官移植受者中的特殊性。